Previously, the company developed and tested a bovine form of AP in three phase II trials in patients with sepsis, AKI and UC.AM-Pharma has since developed and manufactured a proprietary and fully human recombinant form of AP, known as recAP.
Timeline
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
References
Is a
Company attributes
Industry
Location
Total funding amount (USD)
172,843,400
Latest funding round date
July 2019
